Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > September 24, 2020
Daily News
September 24, 2020
- LTL Pharma Looks to Acquire More Off-Patent Brands with Dellegra as a Catalyst
September 24, 2020
- Opdivo Improves PFS in 1st Line Gastric Cancer: Asian PII/III Trial
September 24, 2020
- Padcev Extends Survival in Bladder Cancer, Trial Stopped Early: Astellas/Seattle Genetics
September 24, 2020
- Sun Pharma Launches Ilumya; Its First Innovative Med in Japan
September 24, 2020
- Sumitomo Dainippon Sets Up Subsidiary in Taiwan
September 24, 2020
- Health Minister Ready to Discuss Telemedicine Rollout, but Wants to Ensure Peace of Mind for Patients
September 24, 2020
- Avigan Hits Primary Goal for Novel Coronavirus, Filing Eyed in October: Fujifilm
September 24, 2020
- PMDA to Continue Remote GCP/Compliance Inspections through End of March 2021
September 24, 2020
- Lenvima/Keytruda Combo Shows around 30% ORR in Triple Negative Breast Cancer, Ovarian Cancer: PII
September 24, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…